G protein-coupled receptors (GPCRs) are one of the most promising drug targets due to their pathophysiological role in the human body. However, at the same time, GPCRs have proven to be one of the most challenging targets for antibody drug development. In this webinar, we describe the use of next-generation DNA synthesis tools to overcome the DNA bottleneck in antibody-based GPCR drug discovery. We describe the discovery and creation of both antagonistic and agonistic GLP-1R antibodies by panning this GPCR-focused phage display library on a GLP-1R overexpressing Chinese hamster ovary cell line. We also demonstrate the in vitro and in vivo functional activity of the antibody candidates.
Lucy J. Xu is the Product Manager for Libraries. She graduated from UC San Diego with a B.S. in Bioengineering Biotechnology. Lucy joined Twist Bioscience’s Research and Development team in 2016 when it was first developing combinatorial variant libraries. She’s collaborated with leaders from small biotechs to big pharmaceuticals to build custom libraries that precisely target their needs. Since then she’s led development efforts to further grow both the site variant and combinatorial variant library products to tackle challenges in antibody engineering, protein engineering and directed evolution.
Melina Mathur is the Product Manager for Biopharma at Twist Bioscience. Before joining Twist, she worked as an investor at Asset Management Ventures, in pipeline and portfolio planning at Genentech, and in RNA therapeutics at Merck. Melina holds a PhD in Bioengineering from Stanford University and a BA in Molecular and Cell Biology from UC Berkeley.
NOW AVAILABLE ON DEMAND